Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Detection and monitoring of ovarian cancer.

Su Z, Graybill WS, Zhu Y.

Clin Chim Acta. 2013 Jan 16;415:341-5. doi: 10.1016/j.cca.2012.10.058. Epub 2012 Nov 16. Review.

PMID:
23165217
2.

Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.

Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW.

J Natl Cancer Inst. 2001 Oct 3;93(19):1458-64.

PMID:
11584061
3.

Discovery and application of protein biomarkers for ovarian cancer.

Gagnon A, Ye B.

Curr Opin Obstet Gynecol. 2008 Feb;20(1):9-13. doi: 10.1097/GCO.0b013e3282f226a5. Review.

PMID:
18196999
4.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

5.

Multiple biomarker panels for early detection of ovarian cancer.

Yurkovetsky ZR, Linkov FY, E Malehorn D, Lokshin AE.

Future Oncol. 2006 Dec;2(6):733-41. Review.

PMID:
17155900
6.

Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma.

Geisler JP, Miller GA, Lee TH, Harwood RM, Wiemann MC, Geisler HE.

J Reprod Med. 1996 Mar;41(3):140-2.

PMID:
8778409
7.

New tumor markers: CA125 and beyond.

Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K.

Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. Review.

PMID:
16343244
8.

Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.

Chang X, Ye X, Dong L, Cheng H, Cheng Y, Zhu L, Liao Q, Zhao Y, Tian L, Fu T, Chen J, Cui H.

Int J Gynecol Cancer. 2011 Jul;21(5):852-8. doi: 10.1097/IGC.0b013e31821a3726.

PMID:
21633297
9.

Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.

Leung F, Dimitromanolakis A, Kobayashi H, Diamandis EP, Kulasingam V.

Clin Biochem. 2013 Oct;46(15):1462-8. doi: 10.1016/j.clinbiochem.2013.03.010. Epub 2013 Mar 23.

10.

HE4 in ovarian cancer: from discovery to clinical application.

Montagnana M, Danese E, Giudici S, Franchi M, Guidi GC, Plebani M, Lippi G.

Adv Clin Chem. 2011;55:1-20. Review.

PMID:
22126021
11.

Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.

Yang Y, Pospisil P, Iyer LK, Adelstein SJ, Kassis AI.

PLoS One. 2008;3(11):e3661. doi: 10.1371/journal.pone.0003661. Epub 2008 Nov 6. Erratum in: PLoS ONE. 2009;4(1). doi: 10.1371/annotation/9fbf88b3-5041-4a5e-b569-bc6c0e5f9c29. Pospisil, Pavel [added].

12.

Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.

Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW.

Cancer Res. 2004 Aug 15;64(16):5882-90.

13.

[Tumor markers in epithelial ovarian cancer].

Di Cocco B, Calabretta F, Alghisi F, Salesi N, Bossone G.

Minerva Ginecol. 2003 Aug;55(4):327-32. Review. Italian.

PMID:
14581857
14.

The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.

Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I, Atanackovic J.

Int J Gynecol Cancer. 2012 Feb;22(2):238-44. doi: 10.1097/IGC.0b013e318234f852.

PMID:
22214964
15.

Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.

Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.

Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.

PMID:
22835718
16.

HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma.

Langmár Z, Németh M, Vleskó G, Király M, Hornyák L, Bösze P.

Eur J Gynaecol Oncol. 2011;32(6):605-10. Review.

PMID:
22335019
17.

Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.

Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC Jr, Mills GB.

Cancer. 1995 Nov 1;76(9):1615-20.

PMID:
8635066
18.

Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers.

Bast RC Jr, Skates S, Lokshin A, Moore RG.

Int J Gynecol Cancer. 2012 May;22 Suppl 1:S5-8. doi: 10.1097/IGC.0b013e318251c97d.

19.

Circulating tumour markers in ovarian tumours.

von Schlippe M, Rustin GJ.

Forum (Genova). 2000 Oct-Dec;10(4):383-92. Review.

PMID:
11535987
20.

Estimation of the usefulness of neoplastic markers TPS and CA 125 in diagnosis and monitoring of ovarian cancer.

Zygmunt A, Madry R, Markowska J, Fischer Z.

Eur J Gynaecol Oncol. 1999;20(4):298-301.

PMID:
10475127

Supplemental Content

Support Center